Oryzon Genomics S.A. (BME:ORY)
Spain
· Delayed Price · Currency is EUR | Market Cap | 247.60M |
| Revenue (ttm) | 7.36M |
| Net Income (ttm) | -2.76M |
| Shares Out | 78.85M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | 95.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 541,906 |
| Average Volume | 307,126 |
| Open | 3.260 |
| Previous Close | 3.220 |
| Day's Range | 3.130 - 3.260 |
| 52-Week Range | 2.430 - 4.020 |
| Beta | 0.36 |
| RSI | 47.42 |
| Earnings Date | Feb 27, 2026 |
About Oryzon Genomics
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is... [Read more]
Financial Performance
In 2024, Oryzon Genomics's revenue was $7.62 million, a decrease of -51.43% compared to the previous year's $15.69 million. Losses were -$3.79 million, 2.39% more than in 2023.
Financial numbers in USD Financial StatementsNews
ORYZON Receives European Medicines Agency Approval to Initiate a Phase II Study of iadademstat in Essential Thrombocythemia
MADRID and CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader in epigeneti...